Posterior Reversible Encephalopathy Syndrome in Early-Stage Breast Cancer

• DOI: 10.1111/tbj.12502
• Publication Date: 2015-09-19T06:14:14Z
• Authors: Rahul Ladwa; Geoffrey Peters; Kieron Bigby; Boris Chern
• Keywords: Breast Neoplasms; Docetaxel; Middle Aged; Trastuzumab; Early-stage breast cancer; Platinum chemotherapy; 2746 Surgery; Carboplatin; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Posterior reversible encephalopathy syndrome; 2724 Internal Medicine; Antineoplastic Combined Chemotherapy Protocols; Humans; 2730 Oncology; Female; Taxoids; Posterior Leukoencephalopathy Syndrome; Neoplasm Staging

Wider use of chemotherapy and targeted agents can be associated with posterior reversible encephalopathy syndrome (PRES). This syndrome is most commonly found in metastatic adenocarcinoma treated with platinum-based analogs and is managed with cessation of the precipitating medication. We present the first case of PRES in early-stage breast cancer and discuss the further management of this condition. Recognition of this condition and correction of identifiable precipitating factor including cessation of relevant medications remains important in its management.